BACKGROUND: Implementation of the 2010 Affordable Care Act (ACA) calls for a collaborative effort to transform the U.S. health care system toward patient-centered and value-based care. To identify how specialty care can be improved, we mapped current U.S. health care utilization in patients with inflammatory bowel diseases (IBD) using a national insurance claims database. METHODS: We performed a cross-sectional study analyzing U.S. health care utilization in 964,633 patients with IBD between 2010 and 2012 using insurance claims data, including pharmacy and medical claims. Frequency of IBD-related care utilization (medication, tests, and treatments) and their charges were evaluated. Subsequently, outcomes were put into the framework of current U.S. guidelines to identify areas of improvement. RESULTS: A disproportionate usage of aminosalicylates in Crohn's disease (42%), frequent corticosteroid use (46%, with 9% long-term users), and low rates of corticosteroid-sparing drugs (thiopurines 15%; methotrexate 2.7%) were observed. Markers for inflammatory activity, such as C-reactive protein or fecal calprotectin were not commonly used (8.8% and 0.13%, respectively). Although infrequently used (11%), anti-TNF antibody therapy represents a major part of observed IBD charges. CONCLUSIONS: This analysis shows 2010-2012 utilization and medication patterns of IBD health care in the United States and suggests that improvement can be obtained through enhanced guidelines adherence.
BACKGROUND: Implementation of the 2010 Affordable Care Act (ACA) calls for a collaborative effort to transform the U.S. health care system toward patient-centered and value-based care. To identify how specialty care can be improved, we mapped current U.S. health care utilization in patients with inflammatory bowel diseases (IBD) using a national insurance claims database. METHODS: We performed a cross-sectional study analyzing U.S. health care utilization in 964,633 patients with IBD between 2010 and 2012 using insurance claims data, including pharmacy and medical claims. Frequency of IBD-related care utilization (medication, tests, and treatments) and their charges were evaluated. Subsequently, outcomes were put into the framework of current U.S. guidelines to identify areas of improvement. RESULTS: A disproportionate usage of aminosalicylates in Crohn's disease (42%), frequent corticosteroid use (46%, with 9% long-term users), and low rates of corticosteroid-sparing drugs (thiopurines 15%; methotrexate 2.7%) were observed. Markers for inflammatory activity, such as C-reactive protein or fecal calprotectin were not commonly used (8.8% and 0.13%, respectively). Although infrequently used (11%), anti-TNF antibody therapy represents a major part of observed IBD charges. CONCLUSIONS: This analysis shows 2010-2012 utilization and medication patterns of IBD health care in the United States and suggests that improvement can be obtained through enhanced guidelines adherence.
Authors: Fanni Rencz; Márta Péntek; Martin Bortlik; Edyta Zagorowicz; Tibor Hlavaty; Andrzej Śliwczyński; Mihai M Diculescu; Limas Kupcinskas; Krisztina B Gecse; László Gulácsi; Peter L Lakatos Journal: World J Gastroenterol Date: 2015-02-14 Impact factor: 5.742
Authors: Balakrishnan S Ramakrishna; Govind K Makharia; Vineet Ahuja; Uday C Ghoshal; Venkataraman Jayanthi; Benjamin Perakath; Philip Abraham; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra Desai; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Mathew Philip; Anna Pulimood; Amarender S Puri; Gautam Ray; Shivaram P Singh; Ajit Sood; Venkatraman Subramanian Journal: Indian J Gastroenterol Date: 2015-03-14
Authors: Welmoed K van Deen; Dominic Nguyen; Natalie E Duran; Ellen Kane; Martijn G H van Oijen; Daniel W Hommes Journal: Qual Life Res Date: 2016-08-31 Impact factor: 4.147
Authors: Joseph D Feuerstein; Konstantinos Papamichael; Sara Popejoy; Adam Nadelson; Jeffrey J Lewandowski; Kathy Geissler; Manuel Martinez-Vazquez; Daniel A Leffler; Kim Ariyabuddhiphongs; Chandrashekhar Thukral; Adam S Cheifetz Journal: Dig Dis Sci Date: 2017-11-17 Impact factor: 3.199
Authors: Thomas Cars; Björn Wettermark; Robert Löfberg; Irene Eriksson; Johan Sundström; Mikael Lördal Journal: J Crohns Colitis Date: 2016-01-05 Impact factor: 9.071
Authors: Layne Dylla; Paco S Herson; Sharon N Poisson; John D Rice; Adit A Ginde Journal: J Stroke Cerebrovasc Dis Date: 2021-01-19 Impact factor: 2.136